🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Resectable Lung Non-Small Cell Carcinoma

Pathological Response After Neoadjuvant Treatment on NSCLC NCT05167487n/a17 sites📍 A Coruña📍 Alicante📍 Badalona Fundación GECP · Tests: Cisplatin, Carboplatin Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC NCT06467617Phase 21 site📍 Beijing Beijing Chest Hospital, Capital Medical University · Tests: Adebrelimab plus albumin-bound paclitaxel, carboplatin and recaticimab Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC NCT07492342Phase 23 sites📍 Beijing📍 Guangzhou📍 Zhejiang Jianxing He · Tests: fulzerasib A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC NCT07586202Phase 223 sites📍 Duarte📍 Irvine📍 Portland Janssen Research & Development, LLC · Tests: Amivantamab, Lazertinib, Carboplatin, Pemetrexed Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients NCT06634199n/a22 sites📍 Ferrol📍 Alicante📍 Badalona Fundación GECP · Tests: Durvalumab Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab NCT07510724n/a2 sites📍 Sankt Pölten📍 Frankfurt am Main Institut für Klinische Krebsforschung IKF GmbH at Krankenha… A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) NCT04302025Phase 238 sites📍 Duarte📍 Irvine📍 Los Angeles Genentech, Inc. · Tests: Alectinib, Entrectinib, Vemurafenib, Cobimetinib, Pralsetinib A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) NCT07652736n/a6 sites📍 Córdoba📍 Jaén📍 Lugo BeOne Medicines · Tests: Tislelizumab 68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC NCT06756217n/a1 site📍 Shanghai Ruijin Hospital · Tests: 68Ga-grazytracer PET/CT Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501） NCT06924398Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Postoperative EGFR-TKI Therapy Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer NCT07251582Phase 32 sites📍 Changsha📍 Changsha Hunan Province Tumor Hospital · Tests: Time of Day-based Assignment for Infusion of Immune Checkpoint Inhibitor (e.g., toripalimab, or pembrolizumab) + platin… Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC NCT06810609Phase 25 sites📍 Freiburg im Breisgau📍 Stuttgart📍 Giessen University Hospital, Bonn · Tests: surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance… A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL) NCT07169708n/a9 sites📍 Kaohsiung City📍 Kaohsiung City📍 Kaohsiung City Ono Pharmaceutical Co., Ltd. Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH) NCT06437977Phase 31 site📍 Shanghai Shanghai Chest Hospital · Tests: SBRT, Toripalimab Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer NCT06743581NA2 sites📍 Montreal📍 Montreal Centre hospitalier de l'Université de Montréal (CHUM) · Tests: Cemiplimab, Dupilumab Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression NCT06269211Phase 22 sites📍 Guangzhou📍 Shanghai Ruijin Hospital · Tests: Toripalimab Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients NCT06987734Phase 21 site📍 Shanghai Shanghai Pulmonary Hospital, Shanghai, China · Tests: Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer NCT06877299Phase 21 site📍 Chengdu Sichuan University · Tests: Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT) Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC. NCT07279935Phase 432 sites📍 Beijing📍 Beijing📍 Beijing AstraZeneca · Tests: Osimertinib+cisplatin or carboplatin + pemetrexed Edit PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC NCT06977074Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: PD-1 inhibitor, Platinum Doublet A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer NCT05913089Phase 210 sites📍 Beijing📍 Beijing📍 Beijing Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Tests: TQB2450 injection + Chemotherapy, TQB2450 injection + Anlotinib Hydrochloride Capsule Effects of Infusion Timing on Treatment Response in Solid Tumors NCT07630168Phase 21 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: PD-1/PD-L1 inhibitor monotherapy - 4 cycles before 12:00PM, PD-1/PD-L1 inhibitor monotherapy - 4 cycles after 3 PM, PD-… AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer NCT05377658Phase 21 site📍 Zhengzhou Henan Cancer Hospital · Tests: AK104, Albumin-Bound Paclitaxel, Carboplatin Multicenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer NCT07855965Phase 29 sites📍 Chengdu📍 Chengdu📍 Chengdu West China Hospital · Tests: Cryo-Thermal Ablation, Toripalimab, Platinum-based doublet chemotherapy Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform NCT06349642n/a3 sites📍 Phoenix📍 Jacksonville📍 Rochester Mayo Clinic · Tests: Biospecimen Collection, Tissue Collection A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC NCT06951464Phase 21 site📍 Chengdu Sichuan University · Tests: BL-B01D1, Almonertinib Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer NCT07410975Phase 21 site📍 Shanghai Shanghai Pulmonary Hospital, Shanghai, China · Tests: sintilimab+IBI310+chemotherapy Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC NCT06088771Phase 1, Phase 21 site📍 New York Icahn School of Medicine at Mount Sinai · Tests: Dupilumab, Cemiplimab Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer NCT06755684Phase 21 site📍 Shanghai Peng Zhang · Tests: Befotertinib combined Bevacizumab, Befotertinib combined platinum-based double chemotherapy Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC NCT06939127Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Neoadjuvant Cryoablation Combined with Tislelizumab and Chemotherapy, Surgery, Adjuvant tislelizumab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy